Product series
The company provides product series for global pharmaceutical companies in drug development and production.
Jiuzhou Pharma is a contract development and manufacturing organization for small-molecule and peptide active pharmaceutical ingredients serving pharmaceutical companies worldwide.
jiuzhoupharma.comCrawled Nov 17, 2026
The company provides product series for global pharmaceutical companies in drug development and production.
The company describes its formulation CDMO services for global pharmaceutical companies in drug development and production.
The company outlines its technical platforms for global pharmaceutical companies in drug development and production.
The company presents its production bases for global pharmaceutical companies in drug development and production.
The company details registration filing and regulatory services for global pharmaceutical companies in drug development and production.
The company highlights its service capabilities for global pharmaceutical companies in drug development and production.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. provides global pharmaceutical companies with end-to-end drug development and production solutions, from pre-clinical CMC to commercialization.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. shares news updates on its global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. provides EHS information disclosure for its global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. provides recruitment contact information for its global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. details its talent development initiatives for global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. offers global pharmaceutical companies comprehensive drug development and production solutions, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. provides regular updates on its services for global pharmaceutical companies, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. outlines its corporate governance structure for global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. details its environmental, social, and governance (ESG) initiatives for global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. describes its global business layout for pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. shares investor relations information about its global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. offers contact details for inquiries about its global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
The company offers a one-stop solution for global pharmaceutical companies, covering preclinical CMC, clinical phases I–III, NDA filing, and commercialization.
The company provides a one-stop solution for global pharmaceutical companies, covering preclinical CMC, clinical phases I–III, NDA filing, and commercialization.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. outlines its code of business conduct for global pharmaceutical CDMO services, including pre-clinical CMC, clinical phases I-III, and NDA to market.
Jiuzhou Pharmaceutical integrates **RayHua** as a group member to oversee its entire supply chain. The move consolidates control over supplier development, material testing, production, quality checks, adverse effect reporting, and customer complaint handling. This vertical integration aims to maintain high product quality standards across the process.
Novartis sells a finished-drugs manufacturing plant in China to contract development and manufacturing organization (CDMO) **Jiuzhou** for **$15.1 million**. The transaction occurs as Novartis prepares to spin off its generics subsidiary, **Sandoz**. The deal supports Jiuzhou’s expansion in pharmaceutical production capabilities.
Biocon’s Malaysian manufacturing upgrades have pushed back U.S. approval of its Mylan-partnered Lantus biosimilar for the second time. CStone Pharmaceuticals’ CEO earned nearly **$20 million** in 2023 despite the company’s lack of revenue. Novartis sold its **Suzhou, China** manufacturing site for **$111 million** to a local buyer amid interest in its U.K. Grimsby facility.
Novartis sells a 10-year-old active pharmaceutical ingredient (API) manufacturing facility in China to a Chinese drugmaker. The move follows the company’s ongoing strategy to divest manufacturing operations to streamline operations and boost profitability. This is the latest in a series of divestitures aimed at reducing costs and improving margins.